Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Indaptus Therapeutics Q3 2026 Results: Net Loss of $1.05M, Loss Narrows

Indaptus Therapeutics reported a net loss of $5.38 million for the nine months ended September 30, 2026, a significant reduction from the $12.74 million loss in the prior year period. The company's cash position strengthened to $26.60 million following significant common stock issuances and preferred stock conversions, while operating expenses decreased across both R&D and G&A categories.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-1.0-3.0
EPS (diluted, $ a share)$-0.01$-2.98

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: INDP. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Indaptus Therapeutics, Inc.: key numbers

Share price
$3.45Close, Nov 16
Market cap
$530M
Shares outstanding
153.6MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Indaptus Therapeutics, Inc.

All →
4:31 PM ET 8-K
Financial Results

Indaptus Therapeutics Financial Results

Indaptus Therapeutics reported its Q3 2026 financial results, highlighting a cash and short-term investment position of approximately $30.6 million following a $24 million private placement. The company is shifting its strategic focus toward neurotechnology and neural-network-based devices for sleep-related conditions while significantly reducing R&D expenses by 82% year-over-year.

“Our strategic objective is to position Indaptus for its next phase of growth by actively pursuing innovative opportunities with significant long-term potential and expanding the Company’s strategic focus into promising areas of medical innovation. We believe the successful completion of our approximately $24.0 million private placement provides an important foundation to advance this vision, giving us the financial resources and strategic flexibility to explore new opportunities and build long-term shareholder value.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board

“We are particularly excited about the opportunity to explore the potential of an innovative neurotechnology- and neural-network-based device for certain sleep-related conditions. We believe this area represents an intriguing opportunity to investigate novel approaches to addressing unmet needs in sleep-related health. Through early-stage research and preclinical evaluation, we hope to further assess its scientific potential and explore a possible development pathway toward a future FDA submission.”

Junyi Dai, Indaptus Therapeutics’ Chief Executive Officer and Chairman of the Board
4:38 PM ET 8-K
Capital Raise

Indaptus Therapeutics Capital Raise of $24M

Indaptus Therapeutics completed a private placement of 20,338,974 shares of common stock for aggregate gross proceeds of approximately $24.0 million. The closing follows a previously announced stock purchase agreement dated September 8, 2026, and a subsequent extension of the outside closing date to October 16, 2026.

Value
$24M
9:06 AM ET 8-K
Capital Raise

Indaptus Therapeutics Capital Raise of $24M

Indaptus Therapeutics entered into notices and consents to extend the closing date of a previously announced $24.0 million private placement of common stock. The 'Outside Date' for the transaction was moved from September 29, 2026, to October 16, 2026, to allow additional time for closing conditions to be satisfied.

Value
$24M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.